Adverse events

Related by string. Adverse Events * ADVERSE . adverse : adverse impacts . adverse effects . adverse determinations / eventing . EVENTS : IN NO EVENT . EVENT GIVING RISE TO * FDA MedWatch Adverse Event . Vaccine Adverse Event . Adverse Event Reporting . Serious Adverse Events . FDA Adverse Event . Vaccine Adverse Events . Serious Adverse Event . Adverse Events Reporting *

Related by context. All words. (Click for frequent words.) 74 events AEs 73 treatment emergent adverse 72 laboratory abnormalities 71 AEs 71 Adverse reactions 70 Hypersensitivity reactions 69 TEAEs 69 hematologic adverse 68 Toxicities 68 events TEAEs 68 events SAEs 68 discontinuations due 68 Serious adverse reactions 67 thromboembolic events 67 severe hypersensitivity reactions 67 infusion reactions 66 hematologic toxicity 66 nasopharyngitis 66 ocular adverse 66 hypersensitivity reactions 66 SAEs 66 oxycodone CR 66 adverse reactions observed 66 ALT flares 65 hypomagnesemia 65 intraocular inflammation 65 febrile neutropenia 65 discontinuations 65 ARCALYST ® 65 diarrhea nausea fatigue 65 Serious AEs 65 FluCAM arm 65 leucopenia 64 adverse reactions 64 Thrombotic events 64 thrombocytopenia 64 Treatment emergent adverse 64 incidence ≥ 64 mg QD 64 posaconazole 64 peripheral sensory neuropathy 63 DLTs 63 TYSABRI treated 63 alpha interferons 63 leukopenia 63 Febrile neutropenia 63 certolizumab 63 ACTEMRA TM 63 toxicities 63 myopathy rhabdomyolysis 63 chlorambucil 63 Peripheral edema 63 lopinavir r arm 63 transaminase elevations 63 Myelosuppression 63 acute gout flares 63 hypoglycemic events 63 adverse reactions incidence 63 hypotension 63 endophthalmitis 63 rizatriptan 63 renal toxicity 63 PREZISTA r 63 headache nasopharyngitis 63 Baseline characteristics 62 mcg BID 62 gout flare 62 hypercalcemia 62 EXJADE 62 hematological toxicity 62 mcg QD 62 treatment emergent AEs 62 hematological adverse 62 neutropenia thrombocytopenia 62 Renal impairment 62 adverse reactions occurring 62 neutropenia 62 TNF antagonists 62 definite stent thrombosis 62 stent thromboses 62 dose limiting toxicities 62 Serious ocular 62 mg BID 62 arterial thromboembolic events 62 venous thromboembolic events 62 elevated ALT 62 QTc prolongation 62 constipation nausea 62 angioedema 62 PREZISTA r arm 61 comparator arm 61 gastrointestinal toxicities 61 hematological toxicities 61 Infusion reactions 61 diarrhea nausea vomiting 61 severe exacerbations 61 peripheral edema 61 nephrotoxicity 61 Lactic acidosis 61 Keppra R 61 receiving XGEVA 61 non hematological toxicities 61 myelosuppression 61 Infusion Reactions Severe 61 RLAI 61 intravenous bisphosphonates 61 ARCOXIA 61 teriflunomide 61 gastrointestinal perforation 61 TORISEL 61 hepatotoxicity 61 Hypotension 61 arthralgia 61 APTIVUS r 61 FOLPI 61 neutropenia dehydration dyspnea 61 gastrointestinal toxicity 61 Postoperative complications 61 tapentadol ER 61 oral olanzapine 61 solifenacin 61 mcg albinterferon alfa 2b 60 thrombotic events 60 hypersensitivity reaction 60 pheochromocytoma 60 ALT elevations 60 mg ustekinumab 60 quetiapine 60 fatigue asthenia 60 tolterodine ER 60 proctitis 60 hypophosphatemia 60 COPD exacerbation 60 PASI scores 60 rFVIIa 60 zolmitriptan 60 abacavir lamivudine 60 gout flares 60 infection nasopharyngitis 60 inflammatory lesions 60 stomatitis 60 receiving VELCADE 60 pruritis 60 thromboembolic complications 60 Hypocalcemia 60 Complication rates 60 Dose limiting toxicities 60 CANCIDAS 60 extrapyramidal symptoms 60 INVANZ 60 triamcinolone 60 #mg BID [001] 60 acneform rash 60 flutamide 60 anaphylactoid reactions 60 nicardipine 60 INVEGA ® 60 mg dose 60 pericardial effusions 60 Stent thrombosis 60 cardiac toxicity 60 antiepileptics 60 cerebrovascular events 60 COPD exacerbations 59 lipid lowering agents 59 paresthesias 59 interferon alfa 2b 59 ZYVOX 59 Anaphylactic reactions 59 clinically meaningful differences 59 danazol 59 beclomethasone dipropionate 59 caspofungin 59 hypokalemia 59 thromboembolism 59 lenalidomide dexamethasone 59 concomitant medications 59 dosage regimens 59 pyrexia mucositis sepsis febrile 59 DOXIL 59 corticosteroid therapy 59 cytopenias 59 myalgia 59 divalproex sodium 59 timepoints 59 active comparator 59 hypocalcemia 59 ARIXTRA 59 paroxetine Paxil 59 mycophenolate mofetil 59 Allergic reactions 59 NOLVADEX 59 mucocutaneous reactions 59 generalized edema 59 pruritus 59 4mg/kg 59 patients receiving ERBITUX 59 hallucinations dyskinesia 59 salmeterol fluticasone 59 Tardive dyskinesia 59 TDF FTC 59 pyrexia 59 PRADAXA 59 CIMZIA ™ 59 enalapril 59 adalimumab 59 CIMZIA TM 59 non metastatic osteosarcoma 59 peginterferon alfa 2b 59 lymphopenia 59 severe neutropenia 59 atazanavir ritonavir 59 liver transaminases 59 8mg/kg 59 ribavirin therapy 59 deep venous thromboses 59 placebo controlled studies 58 REYATAZ r arm 58 anemia neutropenia 58 alemtuzumab treated 58 ACTEMRA 58 Angioedema 58 prednisone prednisolone 58 Severe hypersensitivity reactions 58 6R BH4 58 ketorolac 58 headache abdominal pain 58 Teriflunomide 58 VIIBRYD 58 pericardial effusion 58 dose regimens 58 tolvaptan 58 venlafaxine Effexor 58 #mg doses [002] 58 musculoskeletal pain 58 mcg kg REBETOL 58 biologic DMARD 58 TMC# r 58 non selective NSAIDs 58 oral antidiabetes drugs 58 mg TID 58 lacosamide 58 DAPT 58 candidemia 58 relapsed MM 58 nadroparin 58 virologic failure 58 mg kg dose 58 hyperactivity impulsivity 58 lamotrigine 58 composite endpoint 58 pimecrolimus cream 58 NEUPOGEN 58 anaphylactic reactions 58 LEXIVA r 58 receiving VICTRELIS 58 #mg/day [001] 58 sensory neuropathy 58 RLS symptoms 58 elevated liver enzymes 58 ß blockers 58 risperidone Risperdal 58 Neutropenia 58 renal insufficiency 58 PRADAXA #mg 58 levetiracetam 58 MACCE 58 limiting toxicity 58 pruritus itching 58 plus methotrexate 58 severe renal impairment 58 ertapenem 58 adrenal insufficiency 58 CIMZIA TM certolizumab pegol 58 #mg/m# [001] 58 chills fever headache 58 ipsilateral stroke 58 unresectable HCC 58 headache nausea diarrhea 58 oral prednisolone 58 gemifloxacin 58 BoNTA 58 β blockers 58 tenofovir emtricitabine 58 oxcarbazepine 58 reinfarction 58 PULMICORT RESPULES 58 thrombocytopenia neutropenia 58 KAPIDEX 58 clevidipine 58 plasma uric acid 58 PREMPRO 58 ABC/3TC 58 receiving ISENTRESS 58 acarbose 58 Secondary endpoints 58 sulfasalazine 58 neutropaenia 58 nonfatal MI 58 #mg BID [003] 58 piperacillin tazobactam 58 baseline HbA1c 58 splenectomized patients 58 bone marrow suppression 58 dalteparin 58 chlorthalidone 58 bezafibrate 58 certolizumab pegol 58 tamsulosin 58 ropivacaine 58 RAPTIVA 58 aldosterone antagonists 57 saline placebo 57 antiepileptic drug 57 extrapyramidal disorder 57 neutropenia anemia 57 ALVESCO 57 dose cohorts 57 Serious Adverse Events 57 tacrolimus ointment 57 antimuscarinic 57 receiving INTRON 57 QT prolongation 57 adverse reactions ≥ 57 mg/# h 57 visilizumab 57 anterior uveitis 57 intracranial hemorrhage ICH 57 nonrandomized 57 desvenlafaxine succinate 57 gadobutrol 57 antiandrogen 57 Elevated liver enzymes 57 decitabine 57 hyperkalemia 57 voriconazole 57 mg RDEA# 57 generalized tonic clonic seizures 57 TMP SMX 57 myelodysplastic myeloproliferative diseases 57 oral diclofenac 57 Fludara 57 Exclusion criteria 57 efalizumab 57 Peg IFN 57 placebo controlled clinical trials 57 Elitek 57 thrombophlebitis 57 Hypokalemia 57 lumiracoxib 57 palonosetron 57 AGILECT R 57 somnolence dizziness 57 torsade de pointes 57 adriamycin 57 heparin induced thrombocytopenia 57 Lamictal XR 57 TNF antagonist 57 HBeAg seroconversion 57 MULTAQ 57 Hepatotoxicity 57 ziprasidone 57 conventional antipsychotics 57 Thrombocytopenia 57 LVEF 57 nasopharyngitis headache 57 Severe allergic reactions 57 LPV r 57 angioneurotic edema 57 salmeterol HFA MDI 57 valacyclovir 57 malignancy HCM 57 etanercept 57 prolonged QT interval 57 #mg BID [002] 57 haematologic 57 LATUDA 57 ATACAND 57 diabetic neuropathic pain 57 milrinone 57 LEXIVA 57 Exacerbations 57 zonisamide SR 57 vaccinees 57 NNT = 57 symptomatic hypotension 57 myelosuppressive 57 systemic absorption 57 nadolol 57 H2 receptor antagonists 57 Discontinuations 57 virologic response 57 hepatic adverse 57 dosed orally 57 montelukast 57 hypoglycaemic episodes 57 virological failure 57 plus dexamethasone 57 events MACE 57 endothelin receptor antagonists 57 vasomotor symptoms 57 Neulasta ® 57 binary restenosis 57 aseptic meningitis 57 olanzapine LAI 57 rotigotine 57 mcg doses 57 mucositis 57 placebo dexamethasone 57 OAB symptoms 57 IXEMPRA 57 receiving prophylactic anticoagulation 57 highly emetogenic 57 JANUVIA 57 QTcF 57 achieved ACR# 57 Severe acneform rash 57 onset seizures 57 primidone 57 intravitreal injections 57 Eltrombopag 57 GSK# [001] 57 intermittent dosing 57 asthma exacerbations 57 doxazosin 57 fluvastatin 57 levofloxacin 57 tapentadol IR 57 Torsades de Pointes 57 FOLFIRI 57 ACR# ACR# 57 achieved PASI 57 pleural effusion 57 fluoxetine paroxetine 57 atypical femur fractures 57 superficial bladder cancer 57 Treatment discontinuations due 57 NSTEMI 57 limb spasticity 57 Pulmonary embolism 57 placebo 57 conjunctival hyperemia 57 EDEMA3 57 Herpes infections 57 amiodarone 57 infection sinusitis 57 alfuzosin 57 neurologic symptoms 56 IIIa inhibitor 56 recurrent VTE 56 endoscopic remission 56 venlafaxine XR 56 FOLFOX4 56 latrepirdine 56 thromboembolic 56 octreotide LAR 56 pancytopenia 56 microbiological eradication 56 docetaxel Taxotere ® 56 PRISTIQ 56 INVEGA 56 nonhematologic adverse reactions 56 Index CDAI 56 mycophenolate mofetil MMF 56 ORENCIA 56 CrCl 56 Immune reconstitution syndrome 56 experienced hypomagnesemia 56 NATRECOR R 56 aripiprazole 56 oral allopurinol 56 Neuroleptic Malignant Syndrome NMS 56 proton pump inhibitor PPI 56 FluCAM 56 Dermatologic toxicities 56 Q2W 56 plasma concentrations 56 bronchospasm 56 haloperidol Haldol 56 gastrointestinal adverse reactions 56 cytogenetic responses 56 darunavir r 56 hemorrhagic complications 56 insulin detemir 56 tegaserod 56 COZAAR 56 hemoptysis 56 coadministration 56 symptomatic hyponatremia 56 Perforomist Inhalation Solution 56 REMICADE ® 56 achieved statistical significance 56 plus GP IIb 56 thyrotoxicosis 56 terazosin 56 Flu Cy 56 ORENCIA ® 56 amphotericin B 56 ACTOplus met 56 plus OBT 56 aldosterone antagonist 56 posterior uveitis 56 superficial edema 56 infliximab Remicade 56 Hematologic 56 fosamprenavir 56 seropositive patients 56 darbepoetin alfa 56 non valvular atrial 56 Primary endpoints 56 stable angina 56 anemia leukopenia 56 dermatologic reactions 56 Oral corticosteroids 56 akathisia 56 mg doses 56 VaD 56 budesonide pMDI 56 pegylated interferons 56 gastrointestinal symptoms 56 bosentan 56 acitretin 56 renal impairment 56 tolerability profiles 56 INFERGEN 56 EDSS scores 56 adjunctive placebo 56 FOLPI regimen 56 aminotransferases 56 PREZISTA ritonavir 56 systemic corticosteroid 56 postoperative complications 56 macrolide antibiotic 56 recurrent venous thromboembolism 56 sotalol 56 oxycodone IR 56 PLAVIX 56 idraparinux 56 HbA 1c levels 56 VAPRISOL 56 mometasone furoate 56 rash urticaria 56 BENICAR HCT 56 P = .# 56 pamidronate 56 ruboxistaurin 56 mcg kg 56 corrected QT interval 56 isoproterenol 56 exacerbations 56 overlapping toxicities 56 Erythropoietic therapies may 56 interferon alfa 2a 56 lymphocytosis 56 mg/m2 dose 56 abatacept 56 TYGACIL 56 elotuzumab 56 arterial occlusion 56 ONGLYZA saxagliptin 56 Viread Emtriva 56 hyperbilirubinemia 56 myalgias 56 PEG Interferon alfa 56 myocardial infarctions 56 PROCRIT 56 severe hepatomegaly 56 leukotriene receptor antagonists 56 enoxaparin 56 eosinophilic pneumonia 56 Adalimumab 56 Vaprisol 56 Severe cutaneous 56 delayed CINV 56 BARACLUDE ® 56 neutropenia febrile neutropenia 56 periprocedural 56 adrenal suppression 56 anticholinergics 56 anticonvulsants 56 clinically meaningful improvements 56 FROVA 56 EUFLEXXA R 56 primary immunodeficiency PI 56 abacavir 56 INTEGRILIN R 56 maximal doses 56 mg d 56 reactogenicity 56 plus gemcitabine 56 splenectomized 56 Discontinuation 56 divalproex 56 QT interval prolongation 56 esophagitis 56 anticholinergic medications 56 tumor lysis syndrome 56 adalimumab Humira 56 mcg Albuferon 56 MADRS score 56 VFEND 56 recurrent DVT 56 HBeAg negative patients 56 NATRECOR ® 56 valdecoxib 56 Median survival 56 CCyR 56 headache nausea fatigue 56 symptomatic VTE 56 INTRON 56 moderate renal impairment 56 nausea diarrhea 56 aripiprazole Abilify 56 Discontinuations due 55 tolterodine 55 abciximab 55 perioperatively 55 administered subcutaneously 55 BUPHENYL 55 concomitant AEDs 55 ximelagatran 55 proliferative diabetic retinopathy 55 TRIZIVIR 55 colorectal liver metastases 55 arthralgias 55 ZOSTAVAX 55 KETEK 55 atypical fractures 55 HES CEL 55 virologic breakthrough 55 immunomodulatory therapy 55 ZOMIG 55 ketoconazole 55 granisetron 55 fluconazole 55 infliximab monotherapy 55 GEMZAR 55 oral prednisone 55 antidepressants fluoxetine 55 leukopenia pancytopenia thrombocytopenia 55 aprepitant 55 hepatic dysfunction 55 neutropenic fever 55 induce orthostatic hypotension 55 noninferior 55 alanine aminotransferase 55 QTc 55 venlafaxine 55 AGILECT ® 55 AVELOX 55 myalgia arthralgia 55 sirolimus 55 HIV HCV coinfected 55 cisplatin gemcitabine 55 HBeAg positive 55 acromegalic patients 55 aspartate aminotransferase 55 chronic urticaria 55 IIIa inhibitors 55 μg kg 55 glycated hemoglobin levels 55 Hematologic toxicity 55 advanced adenomas 55 Pegasys ® 55 Eloxatin R 55 Kidney toxicity nephrotoxicity 55 doripenem 55 timepoint 55 LOVENOX R 55 dopamine partial agonist 55 cytogenetic response 55 monotherapy 55 rebleeding 55 factor TNF 55 evaluable subjects 55 EFFEXOR XR 55 lopinavir r 55 necrotizing pancreatitis 55 cholinesterase inhibitor 55 daunorubicin 55 nighttime awakenings 55 continuous intravenous infusion 55 PREZISTA rtv 55 dexamethasone Decadron 55 PEGINTRON TM 55 platelet inhibitor 55 PROMACTA 55 transaminases 55 adjunctive ABILIFY 55 genotypic resistance 55 FAMPYRA 55 antiarrhythmic drugs 55 HMG CoA reductase inhibitors 55 canakinumab 55 neuropsychiatric symptoms 55 peginterferon alfa 55 pathologic fractures 55 INCB# [003] 55 nonvertebral fractures 55 p = NS 55 interstitial pneumonia 55 oral vancomycin 55 adverse reactions irrespective 55 tocilizumab 55 ULORIC 55 ZIAGEN 55 sirolimus stent 55 adefovir 55 pooled comparator 55 pharmacokinetic interactions 55 tardive dyskinesia TD 55 5-FU/LV 55 headache diarrhea nausea 55 MDS MPD 55 APTIVUS 55 clomipramine 55 atazanavir 55 Hycamtin ® 55 quetiapine Seroquel 55 neuroleptic malignant syndrome 55 zidovudine lamivudine 55 refractory NSCLC 55 vasogenic edema 55 DMARDS 55 antiemetics 55 telaprevir dosing 55 Paxil paroxetine 55 steroid dexamethasone 55 piroxicam 55 citalopram Celexa 55 XIENCE V PROMUS Stent 55 galiximab 55 Tolvaptan 55 glatiramer acetate 55 mesalamine 55 febuxostat 55 dose titration 55 invasive aspergillosis 55 VELCADE melphalan 55 ibandronate 55 tricyclic antidepressants 55 tipranavir r 55 alfa 2a 55 Psoriasis Area 55 infliximab 55 peginterferon alfa 2a 55 thromboses 55 telcagepant 55 tiotropium 55 Pharmacokinetic parameters 55 NOXAFIL 55 revascularization procedures 55 FASLODEX 55 quinidine 55 amoxicillin clavulanate 55 aminotransferase elevations greater 55 ddI 55 mitomycin 55 clopidogrel Plavix 55 dyspnea 55 antiepileptic drugs AEDs 55 hepatic failure 55 Virologic failure 55 dacarbazine 55 dizziness nausea diarrhea 55 nonvertebral fracture 55 endometrial hyperplasia 55 ZOLINZA 55 aspartate aminotransferase AST 55 CIMZIA 55 asthenia 55 NPH insulin 55 vandetanib 55 hematologic toxicities 55 olanzapine Zyprexa 55 anaphylactic reactions bronchospasm 55 antiarrhythmic drug 55 dexamethasone 55 included exfoliative dermatitis 55 alpha blocker 55 parecoxib 55 transaminase elevation 55 haloperidol 55 atypical antipsychotic medications 55 ecchymosis 55 APTIVUS ritonavir 55 prednisone prednisolone plus 55 OADs 55 cIAI 55 heavily pretreated 55 mitoxantrone 55 headache vomiting 55 MYLOTARG 55 O PPDS 55 bacteremia 55 fluticasone 55 FOLFIRI alone 55 left ventricular dysfunction 55 post herpetic neuralgia PHN 55 inhaled budesonide 55 syncopal 55 urate lowering therapy 55 ritonavir boosted 55 darunavir ritonavir 55 vWD 54 tamoxifen Nolvadex ® 54 octreotide 54 infusional 54 IOP lowering 54 nasopharyngitis upper 54 anakinra 54 tertile 54 FOLFOX 54 mg/# hours 54 irbesartan 54 AZILECT 54 Hepsera 54 invasive candidiasis 54 AST ALT 54 PRECiSE 54 bolus dose 54 cidofovir 54 thrombotic complications 54 partial remissions 54 recurrent genital herpes 54 nevirapine Viramune 54 Pegasys peginterferon alfa 2a 54 INVEGA ™ 54 PEGylated anti 54 oral levofloxacin 54 STELARA 54 ventricular fibrillation VF 54 oral antidiabetes 54 54 hepatic enzymes 54 sedative hypnotics 54 micafungin 54 ipratropium bromide 54 ACR# responses 54 ONGLYZA 54 morphometric vertebral fractures 54 XGEVA 54 intra articular injection 54 RoACTEMRA 54 incontinence episodes 54 paroxysmal AF 54 neuropsychiatric events 54 placebo p 54 PROVIGIL 54 humanized interleukin 6 54 azathioprine 54 FOSRENOL ® 54 Sodium oxybate 54 symptomatic pulmonary embolism 54 plus MTX 54 somnolence fatigue 54 impaired renal 54 quinolone antibiotics 54 Known hypersensitivity 54 HPA axis suppression 54 unfractionated heparin 54 Mg Uk 54 azelastine 54 dysmenorrhoea 54 calcineurin inhibitors 54 lopinavir ritonavir 54 tipranavir ritonavir 54 venlafaxine ER 54 SUSTENNA TM 54 REYATAZ ritonavir 54 microbleeds 54 pruritus rash 54 primary hypercholesterolemia 54 RRMS patients 54 dysuria 54 μg dose 54 administered concomitantly 54 MYCAMINE 54 angiotensin converting enzyme inhibitors 54 MIRAPEX 54 timolol 54 primary axillary hyperhidrosis 54 urticaria 54 DMARD 54 GnRH agonist 54 Tumor shrinkage 54 antiretroviral naive 54 colorectal adenoma 54 erythema redness 54 fondaparinux 54 metastatic GIST 54 subtrochanteric 54 receiving FUSILEV 54 invasive fungal infections 54 potent CYP#A# inhibitors 54 anemia hemoglobin 54 carotid stenosis 54 hepatic encephalopathy HE 54 polidocanol 54 fatal anaphylactic 54 tirofiban 54 HbA1c levels 54 generalized anxiety disorder GAD 54 serum phosphate levels 54 x ULN 54 INVEGA ® SUSTENNA ® 54 cholecystitis 54 systemic corticosteroids 54 cabergoline 54 phenytoin 54 nondiabetic patients 54 thienopyridines 54 moderately emetogenic 54 #mg dose [001] 54 PENTASA 54 Ophena TM 54 pulmonary infiltrates 54 mEq L 54 systemic embolism 54 placebo p = 54 pramipexole 54 Navelbine 54 venous thrombosis 54 lispro 54 REYATAZ 54 hypereosinophilic syndrome 54 hematologic adverse reactions 54 nitrofurantoins 54 SVR# 54 Folfox 54 non splenectomized 54 budesonide 54 hyperphenylalaninemia HPA due 54 WARNINGS Myopathy Rhabdomyolysis 54 recurrent glioblastoma multiforme 54 histologic subtype 54 ceftriaxone 54 Seroquel quetiapine fumarate 54 risperidone olanzapine 54 Venous thromboembolism 54 postoperative complication 54 lamivudine 54 Engerix B 54 ARB telmisartan 54 Tindamax R 54 prucalopride 54 vinorelbine 54 docetaxel Taxotere R 54 sitaxsentan 54 docetaxel chemotherapy 54 somnolence sedation 54 ileus 54 severe hypoglycemic 54 retrograde ejaculation 54 KOMBIGLYZE XR 54 receiving PEGINTRON 54 lipid parameters 54 RSD# oral 54 CsA 54 proximal DVT 54 peg IFN 54 histologies 54 glimepiride 54 p = #.# [004] 54 fluticasone salmeterol 54 BROVANA 54 dyspareunia 54 hypersensitivity reactions eg anaphylaxis 54 epistaxis 54 Keppra ® 54 MCyR 54 linaclotide treated 54 â ‰ ¥ 54 VIBATIV 54 fluorouracil leucovorin 54 #mg QD [002] 54 pegylated liposomal doxorubicin 54 somatostatin analog 54 LMWH 54 hepatorenal syndrome 54 tenofovir DF 54 QT QTc 54 3TC lamivudine Epivir 54 systemic hypotension 54 cytogenetic abnormalities 54 coadministered 54 doxorubicin cyclophosphamide 54 tiotropium bromide 54 anti arrhythmic drug 54 Sporanox 54 REVLIMID ® 54 INTEGRILIN 54 Recurrences 54 LEVAQUIN ® 54 oral rivaroxaban 54 GERD symptom 54 ARCALYST 54 paliperidone ER 54 bleeding ulceration

Back to home page